Vessel Due ip injection 600ed / 2ml 2ml amp 10 pcs


Vessel Due ip injection 600ed / 2ml 2ml amp 10 pcs



Active substance:
Sulodexide 600 LE * – lipoproteinlipaznaya unit.
Sodium chloride 18 mg Water for Injection to 2 ml.
Light yellow or yellow transparent solution.
Product form:
Solution for intravenous and intramuscular administration, the LE 600/2 ml.
2 ml of a dark glass vial with a line of fracture. 5 vials in each of two contour of cellular packages or 10 vials in one contour cellular packaging with instructions for medical use in a cardboard package.
– hypersensitivity; – hemorrhagic diathesis and diseases accompanied by reduced blood clotting; – I trimester of pregnancy.
Precautions: – In a joint application with anticoagulants of clotting parameters should be monitored.
– angiopathy with an increased risk of thrombotic events, including after suffering a myocardial infarction; – the cerebral circulation, including the acute phase of ischemic stroke and the early recovery period; encephalopathy caused by atherosclerosis, diabetes, hypertension; vascular dementia; – peripheral arterial occlusive disease like atherosclerosis and diabetic origin; – phlebopathy, deep vein thrombosis; – microangiopathy (nephropathy, retinopathy, neuropathy), and macroangiopathy in diabetes (diabetic foot syndrome, encephalopathy, cardiomyopathy); – thrombophilic state, antiphospholipid syndrome (administered together with acetylsalicylic acid, and after LMWH); – the treatment of heparin-induced thrombocytopenia, thrombotic, because it does not cause or aggravate it.
Interaction with other drugs
Significant drug interactions Vessel® Due F with other drugs is not established. In the application of sulodexide it is not recommended to use both drugs affecting hemostasis as anticoagulants (direct and indirect).
Bleeding is the only phenomenon that can occur when an overdose. In the case of bleeding must administering protamine sulphate (1% solution) applied at bleedings caused by heparin.
pharmachologic effect
Pharmacological group:
Anticoagulants – heparin and its derivatives.
Pharmacological properties:
Vessel® Due F (sulodexide) is a biological drug, which is a natural mixture of glycosaminoglycans (GAGs) heparin fraction with a molecular weight of 8,000 daltons (80%) and dermatan sulfate (20%).
The mechanism of action of sulodexide is due to two main characteristics: a high-speed heparin fraction has an affinity for antithrombin III (ATIII) and dermatanovaya – to heparin cofactor II (KGII).
Angioprotective, pro-fibrinolytic, anticoagulant, antithrombotic effect.
Angioprotective effect due to the reduction of the structural and functional integrity of the vascular endothelial cells with recovery of normal density of negative electric charge pore basal vascular membrane. Furthermore, the preparation normalizes blood rheology by reducing triglycerides (stimulates lipolytic enzyme – lipoprotein lipase, the hydrolysis of triglycerides belonging to the LDL).
The efficacy of the drug for diabetic nephropathy sulodexide determined by the ability to reduce the thickness of the basement membrane and extracellular matrix production by reducing the proliferation of mesangium cells.
Profibrinolytic effect due to an increase in blood levels of tissue plasminogen activator and its inhibitor content reduction.
Anticoagulant effect solution for intravenous and intramuscular administration that is weakly expressed in the proposed dosage (one ampoule per day) appears due to the affinity to antithrombin and heparin cofactor II, which successively lowers the concentration of activated factor X and thrombin.
Antithrombotic activity – the result of all the actions that sulodexide exerts on the vascular wall (angioprotective action), fibrinolysis (profibrinolytic effect), blood coagulation (weakly expressed anticoagulant activity) and inhibition of platelet adhesion.
The absorption of sulodexide is administered intravenously or intramuscularly quite fast and depends on blood flow velocity in the injection site.
Concentration in plasma after sulodexide internal bolus in a single dose of 50 mg after 15, 30 and 60 minutes was 3.86 ± 0.37 mg / L, 1.87 ± 0.39 mg / L and 0.98 ± 0.09 mg / L respectively. Sulodexide is distributed in the vascular endothelium at a concentration of 20-30 times the concentration in other tissues. It is metabolized in the liver and excreted mainly by the kidneys. In the study of radioactive labeled drug sulodexide 55.23% excreted in urine during the first 96 hours.
Pregnancy and breast-feeding
When pregnancy is appointed under the strict supervision of a physician. There is a positive experience with the drug for the treatment and prevention of vascular complications in patients with type I diabetes in II and III trimesters of pregnancy, the development of late toxicosis pregnant.
Conditions of supply of pharmacies
side effects
According to clinical studies
Data on the frequency of adverse drug reactions associated with the use of sulodexide, were obtained in clinical trials involving patients treated with standard doses of the drug at the usual duration of therapy course.
Adverse reactions associated with the use of sulodexide, were classified by system-organ class and distributed in frequency of occurrence as follows: Very common (> 1/10), common (> 1/100 to 1/1000 to 1/10000 to
Nervous system: rarely – headache, very rare – loss of consciousness.
organ of hearing: often – dizziness.
Gastrointestinal tract: often – pain in the upper abdomen, diarrhea, nausea, rarely – a feeling of abdominal discomfort, dyspepsia, flatulence, vomiting, very rarely – gastric bleeding.
Allergic reactions: often – a rash of various localization, rarely – eczema, erythema, urticaria.
General disorders and at the injection site: rare – pain at the injection site hematoma at the injection site, rarely – peripheral edema.
According to postmarketing observations.
During post-marketing use of sulodexide have been reported more adverse events. The frequency of the undesirable effects of data can not be estimated due to the fact that information about them comes in the form of spontaneous messages. Accordingly, the frequency of these adverse events are classified as “unknown” (may not be calculated on the basis of the available data).
On the part of the psyche: derealization.
From the nervous system: convulsions, tremor.
On the part of the organ of vision: visual disturbances.
Cardio-vascular system: palpitations, flushing.
The respiratory system, thorax and mediastinum: hemoptysis.
Skin and subcutaneous tissue disorders: pruritus, purpura, erythema generalized.
From the urinary system: bladder neck stenosis, dysuria.
General disorders and at the injection site: pain in the chest, pain, a burning sensation at the injection site.
special instructions
At the beginning and end of the treatment it is advisable to define the following parameters: activated partial thromboplastin time, antithrombin III of, bleeding time and clotting time. Due F increases Vessel® normal levels of activated partial thromboplastin time approximately half.
Effect on the ability to drive mechanisms and
On the ability to drive vehicles and mechanisms of drug
Vessel® Due F is not affected.
Storage conditions
At a temperature of not higher than 30 ° C.
Keep out of the reach of children!.
Dosing and Administration
1 ampoule per day, intramuscularly or intravenously, for 15-20 days.
Then therapy should continue for 30-40 days of taking the drug inside the dosage form in the form – the capsule. Assign 1-2 capsules 2 times a day before meals.
A full course of treatment should not be repeated at least 2 times a year.
Depending on the results of clinical and diagnostic examination of a patient, the physician’s discretion dosing regimen can be changed.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review